# Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients

> **NCT04076228** · — · COMPLETED · sponsor: **Kiang Wu Hospital** · enrollment: 37 (actual)

## Conditions studied

- NSCLC Stage IV

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04076228
- **Lead sponsor:** Kiang Wu Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-01
- **Primary completion:** 2020-01-01
- **Final completion:** 2020-01-01
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2020-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04076228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04076228, "Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04076228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*